Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

A specific gene mutation causes vitamin D resistance, but certain vitamin D analogs might help.

Linagliptin may cause hair loss and skin blisters.

Some blood thinners and blood pressure medicines can cause hair loss, which usually starts 1 to 6 months after beginning the medication.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

Levetiracetam often causes behavioral issues, while oxcarbazepine is more likely to cause sleepiness in epilepsy patients.

ExoFlo is safe and effective for treating Complex Regional Pain Syndrome symptoms.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

Onyx® embolization effectively treats facial arteriovenous malformations with minimal complications.

Current treatments for recurrent ischemic priapism are not well-defined and need more research.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.